Literature DB >> 23640184

Challenges in pharmacogenetics.

Ingolf Cascorbi1, Oliver Bruhn, Anneke N Werk.   

Abstract

The attempt to optimize drug treatment of patients by using evidenced-based medicine considering individual physiological and disease-related conditions is standard of modern medicine. Pharmacogenetics (PGx) has contributed to individualization considering hereditary genetic information; however, increasingly, pharmacogenomics is becoming essential, particularly in relation to modern oncology. New technologies such as next-generation sequencing and rapid development of computational and information sciences will help to better elucidate the consequences of genetic variation, considering also epigenetics and gene-environmental interactions and their translation into clinically relevant individual phenotypes. This review highlights the current challenging and most promising examples of PGx.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23640184     DOI: 10.1007/s00228-013-1492-x

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  48 in total

1.  The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.

Authors:  K A Kim; P W Park; S J Hong; J-Y Park
Journal:  Clin Pharmacol Ther       Date:  2008-03-05       Impact factor: 6.875

2.  A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain.

Authors:  Bruno Georg Oertel; Mattias Kettner; Klaus Scholich; Christoph Renné; Bianca Roskam; Gerd Geisslinger; Peter Harald Schmidt; Jörn Lötsch
Journal:  J Biol Chem       Date:  2008-12-30       Impact factor: 5.157

3.  High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases.

Authors:  A L Zackrisson; B Lindblom; J Ahlner
Journal:  Clin Pharmacol Ther       Date:  2009-11-11       Impact factor: 6.875

4.  The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations.

Authors:  Laure Elens; Dennis A Hesselink; Ron H N van Schaik; Teun van Gelder
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

5.  Association of UDP-glucuronosyltransferase 1A9 (UGT1A9) gene polymorphism with kidney allograft function.

Authors:  Joanna Pazik; Monika Ołdak; Marcin Dąbrowski; Zbigniew Lewandowski; Elżbieta Sitarek; Marta Podgórska; Ewa Ważna; Rafał Płoski; Jacek Szmidt; Andrzej Chmura; Magdalena Durlik; Jacek Malejczyk
Journal:  Ann Transplant       Date:  2011 Oct-Dec       Impact factor: 1.530

6.  The genetic determinants of the CYP3A5 polymorphism.

Authors:  E Hustert; M Haberl; O Burk; R Wolbold; Y Q He; K Klein; A C Nuessler; P Neuhaus; J Klattig; R Eiselt; I Koch; A Zibat; J Brockmöller; J R Halpert; U M Zanger; L Wojnowski
Journal:  Pharmacogenetics       Date:  2001-12

7.  Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.

Authors:  Dietmar Trenk; Willibald Hochholzer; Martin F Fromm; Oliver Zolk; Christian M Valina; Christian Stratz; Franz-Josef Neumann
Journal:  Circ Cardiovasc Genet       Date:  2011-06-17

8.  Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment.

Authors:  Thomas Rau; Roland Heide; Klaus Bergmann; Henrike Wuttke; Ulrike Werner; Nico Feifel; Thomas Eschenhagen
Journal:  Pharmacogenetics       Date:  2002-08

Review 9.  miRNAs as mediators of drug resistance.

Authors:  Sierk Haenisch; Ingolf Cascorbi
Journal:  Epigenomics       Date:  2012-08       Impact factor: 4.778

Review 10.  The cancer genome.

Authors:  Michael R Stratton; Peter J Campbell; P Andrew Futreal
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

View more
  4 in total

Review 1.  Current review of genetics of human obesity: from molecular mechanisms to an evolutionary perspective.

Authors:  David Albuquerque; Eric Stice; Raquel Rodríguez-López; Licíno Manco; Clévio Nóbrega
Journal:  Mol Genet Genomics       Date:  2015-03-08       Impact factor: 3.291

Review 2.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

3.  Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature.

Authors:  Elizabeth J J Berm; Margot de Looff; Bob Wilffert; Cornelis Boersma; Lieven Annemans; Stefan Vegter; Job F M van Boven; Maarten J Postma
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

Review 4.  Pharmacogenetic and pharmacogenomic discovery strategies.

Authors:  Concetta Crisafulli; Petronilla Daniela Romeo; Marco Calabrò; Ludovica Martina Epasto; Saverio Alberti
Journal:  Cancer Drug Resist       Date:  2019-06-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.